Allarity Therapeutics ALLR
單位：USD
1.08
0.03
(2.86%)
單位：美金千元
| 科目 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | 2023/Q2 | 2023/Q1 | 2022/Q4 | 2022/Q3 | 2022/Q2 | 2022/Q1 | 2021/Q4 | 2021/Q3 | 2021/Q1 | 2020/Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
營業收入淨額
| - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
營業成本
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
營業毛利
| - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
營業費用
| 3,036 | - | 12,313 | 3,371 | 4,240 | 4,879 | 4,426 | 4,156 | 3,659 | 6,750 | 4,562 | 4,842 | 18,309 | 15,087 | 4,193 | 2,462 | 2,749 |
研發費用
| 1,403 | 1,847 | 1,021 | 1,058 | 2,170 | 2,623 | 1,948 | 1,105 | 1,427 | 941 | 3,004 | 1,696 | 1,289 | 8,867 | 1,574 | 1,251 | 1,893 |
推銷及管理費用
| 1,633 | 5,470 | 1,589 | 2,313 | 2,070 | 2,256 | 2,478 | 3,051 | 2,232 | 2,245 | 1,558 | 3,146 | 3,013 | 6,220 | 2,619 | 1,211 | 856 |
非經常性項目費用
| - | - | 9,703 | - | - | - | - | - | - | 3,564 | - | - | 14,007 | - | - | - | - |
其他營業費用
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
營業利益
| -3,036 | -7,317 | -12,313 | -3,371 | -4,240 | -4,879 | -4,426 | -4,156 | -3,659 | -6,750 | -4,562 | -4,842 | -18,309 | -15,087 | -4,193 | -2,462 | -2,749 |
其他收入及費用
| 361 | -61 | 396 | 2,168 | 495 | 3,470 | 13 | 1,918 | 408 | 3,725 | -435 | -224 | 14,041 | - | - | - | - |
利息費用
| 57 | 75 | 50 | 426 | 102 | 230 | 34 | 142 | 101 | 116 | 35 | 33 | 39 | 18 | 0 | 79 | 112 |
稅前純益
| -2,732 | -7,453 | -11,967 | -1,629 | -3,847 | -1,639 | -4,447 | -2,380 | -3,352 | -3,141 | -5,032 | -5,099 | -4,307 | -19,468 | 1,266 | -3,052 | -1,817 |
所得稅
| - | - | -377 | - | -4 | 83 | - | - | - | -303 | 5 | 4 | -1,227 | 1,194 | -406 | 33 | -641 |
稅後純益
| -2,732 | -7,453 | -11,590 | -1,629 | -3,843 | -1,722 | -4,447 | -2,380 | -3,352 | -2,838 | -5,037 | -5,103 | -3,080 | -20,662 | 1,672 | -3,085 | -1,176 |
基本每股稅後盈餘(元)
| -0.25 | -4.63 | -7.71 | -2.2 | -1.11 | - | -2.24 | -19.44 | -2.82 | 0 | -0.02 | -1.54 | -19.64 | - | 0.21 | -0.68 | 0.21 |
稀釋每股稅後盈餘(元)
| -0.25 | 9.68 | -3.43 | 21.41 | -1.11 | 9.33 | 47.44 | 251.01 | -7.95 | -0.26 | -1.88 | 0.49 | -0.56 | -2.49 | 0.21 | -0.68 | 0.21 |
基本平均股數(千股)
| 11,146 | 599 | 1,575 | 748 | 3,505 | - | 2,475 | 503 | 1,188 | 7,640,194 | 359,105 | 4,208 | 236 | - | 8,075 | 4,533 | 8,075 |
稀釋平均股數(千股)
| 11,146 | - | 1,575 | 748 | 3,505 | - | 2,475 | 503 | 1,188 | 7,640,194 | 359,105 | 4,208 | 236 | - | 8,075 | 4,533 | 8,075 |
還原基本每股稅後盈餘(元)
| -0.25 | -4.63 | -7.71 | -66 | -664.16 | - | -1,346.09 | -11,663.89 | -67,798.28 | -252.01 | -15,624.39 | -1,293,632.34 | -16,497,760.44 | - | 173,884.35 | -571,214.28 | 173,884.35 |
還原稀釋每股稅後盈餘(元)
| -0.25 | 9.68 | -3.43 | 642.26 | -664.16 | 5,599.44 | 28,465.26 | 150,604.86 | -190,700.87 | -216,147.61 | -1,581,506.15 | 412,823.28 | -471,407.14 | -2,091,736.29 | 173,884.35 | -571,214.28 | 173,884.35 |
還原基本平均股數(千股)
| 11,146 | 599 | 1,575 | 24 | 5 | - | 4 | 0 | 0 | 9 | 0 | 0 | 0 | - | 0 | 0 | 0 |
還原稀釋平均股數(千股)
| 11,146 | - | 1,575 | 24 | 5 | - | 4 | 0 | 0 | 9 | 0 | 0 | 0 | - | 0 | 0 | 0 |
EBITDA(千元)
| -2,664 | -7,377 | -11,912 | -1,202 | -3,743 | -1,400 | -4,404 | -2,229 | -3,241 | -3,023 | -4,986 | -5,042 | -4,245 | -19,434 | 1,303 | -2,917 | -1,769 |
